Video

COPHy 2023: Durability associated with multi-target therapies is superior to anti-VEGF mono-target therapy in AMD

Author(s):

Antonio Campos, MD, PhD, discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®

Antonio Campos, MD, PhD, made a presentation at the Congress on Controversies in Ophthalmology. He discusses his position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD with David Hutton, Executive Editor, Ophthalmology Times.®

Video transcript

Editor’s note: This transcript has been edited for clarity

David Hutton:

Hello, I'm David Hutton of Ophthalmology Times.® The 14th annual Congress on controversies in Ophthalmology is being held this year in Lisbon, Portugal. At the event physicians present the pros and cons on a number of topics. Dr. Antonio Campos defended the negative position on a discussion titled Durability Associated with Multi-target Therapies is Superior to anti-VEGF Mono-target Therapy in AMD. Thanks for joining us today. Tell us about your discussion.

Antonio Campos, MD, PhD:

This is related mainly with the new faricimab versus aflibercept. And we know that angiopoietin-2 is not elevated in several cases of AMD, and 42% of the patients in the TENAYA and LUCERNE studies didn't have actually angiopoietin-2 levels elevated. Besides, there's another blocker of angiopoietin-2 that was used in ONYX trial of nesvacumab that didn't prove to be effective. And one should expect that in diabetic retinopathy studies and the recent BALATON and communal studies of retinal vein occlusion, where angiopoietin-2 is really elevated that the dual-action blocking angiopoietin-2 should have better results. But actually, that didn't prove to be right. So we must not forget that faricimab has a higher dosage than aflibercept [inaudible]. Well, the completion of the study was not perfect, and probably dosage and bioavailability will respond for most of the differences. According to my position, regulatory authorities, such as FDA and MA in Europe, also pointed out that it's not proven that there is an effective dual blocking mechanism in those medicines.

*Anat Loewenstein presented the affirmative position on this topic.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.